Bristol Myers Squibb (CELG-RI) Operating Expenses (2009 - 2026)

Bristol Myers Squibb has disclosed Operating Expenses across 18 years of filings, most recently posting $8.2 billion for Q1 2026.

• In Q1 2026, Operating Expenses changed 0.24% year-over-year to $8.2 billion; the TTM figure through Mar 2026 stood at $38.9 billion (down 6.36% YoY), while the FY2025 annual figure was $38.9 billion, down 31.43% from the prior year.
• Operating Expenses declined to $8.2 billion in Q1 2026, from $11.0 billion in the prior quarter.
• Over the last five years, Operating Expenses for CELG-RI reached as high as $23.4 billion in Q1 2024 and fell as low as $8.2 billion in Q1 2025.
• The 5-year median for Operating Expenses is $9.8 billion (2023), against an average of $10.5 billion.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 172.92% — and 2025, when it tumbled 64.8%.
• A 5-year view of Operating Expenses shows it stood at $9.5 billion in 2022, then advanced by 2.68% to $9.8 billion in 2023, then grew by 24.12% to $12.2 billion in 2024, then declined by 9.33% to $11.0 billion in 2025, then declined by 25.22% to $8.2 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $8.2 billion, $11.0 billion, and $9.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.